Clinical Trials List
Protocol Number1336-0011
Completed
2020-03-01 - 2023-12-31
Phase I
Recruiting2
-
Trial Applicant
Boehringer Ingelheim
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Jih-Hsiang Lee Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of Hematology & Oncology
- 楊景堯 Division of Hematology & Oncology
- Chiun Hsu Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- JIN-YUAN SHIH Division of Hematology & Oncology
- 許嘉林 Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
- YEN-TING LIN Division of Hematology & Oncology
- James Chih-Hsin Yang Division of Hematology & Oncology
- Chong-Jen Yu Division of Hematology & Oncology
- 蔡子修 Division of Hematology & Oncology
- Ann-Lii Cheng Division of Hematology & Oncology
- YU-YUN SHAO Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- 廖唯昱 Division of Hematology & Oncology
- 吳尚俊 Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chien-Chung Lin Division of General Internal Medicine
- Shang-Yin Wu Division of General Internal Medicine
- Jui-Hung Tsai Division of General Internal Medicine
- Yu-Min Yeh Division of General Internal Medicine
- Chun-Hui Lee Division of General Internal Medicine
- Wen-Pin Su Division of General Internal Medicine
- Po-Lan Su Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
255 participants
